| Type | MNC (JVs and subsidiaries) |
|---|---|
| Industry | Pharmaceutical |
| Founded | 1983 |
| Headquarters | Hinjwadi, Pune, India |
| Key people | Satish Mehta [1] CEO |
| Products | Tablets, Capsules, Soft gels, Injectables, Lyophilized sterile parenterals, Onco products |
| Employees | approximately 9000 |
| Website | www.emcure.co.in |
Emcure Pharmaceuticals headquartered at Pune in West India is a vertically integrated Indian pharmaceutical company. The company's products include Tablets, Capsules ( both Softgel capsules and hard-gel capsules), and injectables. Emcure has proven capabilities to research, develop and supply finished formulations to the most demanding needs of the global regulated markets.
Contents |
USA - The company has a manufacturing facility and R&D centre at East Brunswick, New Jersey, USA.
Emcure is planning to raise money through an initial public offering [2]
Pharma Division
1. Orofer XT ( Ferrous Ascorbate) 2. Emsulide P 3. Asomex (Chirally pure S-amlodipine) 4. Pause (Tranexemic Acid) 5. Infen (Dexketoprofen) 6. Dexpure 7. Xplod 8. Metpure 9. C-zid 10. Velidex 11. Exhep
Emcure voices its concerns on HIV/AIDS through its "Let's fight AIDS together" initiative and supplies Antiretroviral drugs to Africa, Asia Pacific and CIS. As a part of its corporate social responsibility it supports 'Taal', a pharmacy for HIV/AIDS patients run by HIV/AIDS patients.
Emcure has license agreements with Bristol-Myers Squibb for Atazanavir [3] and Gilead Sciences for Tenofovir [4] as part of their Global Access Programs.